<DOC>
	<DOCNO>NCT02784535</DOCNO>
	<brief_summary>Drug therapy patient suffer autonomic failure neurogenic orthostatic hypotension scarce effective . If leave untreated , patient high risk syncope , fall fall-related injury . The propose study determine clinical benefit commercially available drug , atomoxetine , reduce symptom associate neurogenic orthostatic hypotension patient autonomic failure .</brief_summary>
	<brief_title>Norepinephrine Transporter Blockade , Autonomic Failure ( NETAF )</brief_title>
	<detailed_description>Autonomic failure group rare neurodegenerative disorder primarily affect autonomic nervous system . These patient develop neurogenic orthostatic hypotension ( OH ) impair autonomic reflex control cardiovascular neuro-humoral adaptation upright posture . The treatment neurogenic OH challenging ; therapeutic option scarce , patient refractory treatment . Atomoxetine selective norepinephrine transporter inhibitor increase availability norepinephrine synapse block reuptake . Our preliminary data sixty-five patient primary autonomic failure neurogenic OH show atomoxetine effective midodrine , standard care , improve stand SBP ( +7.5 mm Hg ) . Notably , atomoxetine midodrine induce significant reduction OH-related symptom ( lightheadedness dizziness ) compare placebo . In proposal , test hypothesis prolong administration norepinephrine transporter blocker , atomoxetine , improve OH-related symptom OH-impact daily activity compare placebo autonomic failure patient . We propose randomize , double-blind , placebo-controlled , 2x2 crossover study .</detailed_description>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Pure Autonomic Failure</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>40 80 year old Neurogenic Orthostatic Hypotension ( define reduction ≥30 mmHg drop SBP within 3 minute stand , associate impaired autonomic reflex assess autonomic function test . Pregnancy breastfeed Hypersensitivity atomoxetine ( severe allergic reaction , rash , urticaria , anaphylaxis ) Use norepinephrine transporter inhibitor Wellbutrin ( Bupropion ) , Cymbalta ( Duloxetine ) , Effexor ( venlafaxine ) , Pristiq ( desvenlafaxine ) , Savella ( milnacipran ) Previous history ( within 14 day prior enrollment ) current use monoamine oxidase inhibitor Concomitant use strong CYP2D6 inhibitor delavirdine , paroxetine , fluoxetine , quinidine Preexisting sustain severe hypertension ( BP ≥ 140/80 mmhg sit position ) Impaired hepatic function ( aspartate amino transaminase [ AST ] and/or alanine amino transaminase [ ALT ] &gt; 2 x upper limit normal range ) Impaired renal function ( serum creatinine equal 1.6 mg/dl ) Myocardial infarction within 6 month prior enrollment Congestive heart failure ( LV hypertrophy acceptable ) History serious neurologic disease cerebral hemorrhage , stroke Inability comply protocol , e.g. , uncooperative attitude , inability return followup visit , unlikelihood completing study , mental condition render subject unable understand nature , scope , possible consequence study Narrowangle glaucoma</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>